Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay

MT Newswires Live

04/01

Arovella Therapeutics (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer

cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.

The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.

The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.

The company's shares rose nearly 3% in recent trading on Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2624636785"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624636785\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624636785?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624636785","market":"sg","top_or_hot":-1,"title":"Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ALA.AU\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer</p><p>cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.</p><p>The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.</p><p>The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.</p><p>The company's shares rose nearly 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-01 10:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ALA.AU\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer</p><p>cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.</p><p>The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.</p><p>The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.</p><p>The company's shares rose nearly 3% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALA.AU","symbol_name":"AROVELLA THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2624636785","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624636785","pubTimestamp":1775011349,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics  confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor , which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T  cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALA.AU":"AROVELLA THERAPEUTICS LTD","BK4022":"陆运","BK4539":"次新股","BK7096":"制药","CAR":"安飞士","BK4230":"旅客陆运","BK7503":"科技股","BK7002":"互动媒体与服务","BK4139":"生物科技","CAR.AU":"CAR GROUP LTD","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"Arovella Therapeutics在体外试验中证实了靶向Claudin 18.2的CAR抗胰腺癌、胃癌的功能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALA.AU":1,"LENZ":1.5,"CAR":1.5,"CAR.AU":1},"content_text":"Arovella Therapeutics (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}